Real-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey study
![Thumbnail](/xmlui/themes/Mirage2//images/restricted.png)
View/ Open
Access
info:eu-repo/semantics/embargoedAccessDate
2022Author
Artaç, MehmetÇubukçu, Erdem
Bozkurt, Oktay
Bilici, Ahmet
Çelik, S.
Özçelik, M.
Öven, B.
Şimşek, E.
Geredeli, C.
Karaca, M.
Cil, T.
Harputluoğlu, Hakan
Şendur, Mehmet Ali Nahit
Türk, H. Mehmet
Kefeli, Umut
Alacacıoğlu, Ahmet
Tural, D.
Sakin, A.
Karadurmuş, Nuri
Çevik, Duygu
Dane, Faysal
Gümüş, Mahmut
Metadata
Show full item recordCitation
Artaç, M., Çubukçu, E., Bozkurt, O., Bilici, A., Çelik, S., Özçelik, M. ... Gümüş, M. (2022). Real-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey study. Annals of Oncology içinde (S281-S282. ss.). https://doi.org/10.1016/j.annonc.2022.04.182Abstract
Background: Randomized clinical trials showed that maintenance chemotherapy plus biologics in patients with mCRC could increase the progression free survival (PFS) without any advantage for overall survival (OS). Our aim was to study the real-life experience (onco-colon registry Turkey) of maintenance chemotherapy with antiEGFR or antiVEGF mAbs after the standart firstline doublet chemotherapy backbone in RAS wild-type mCRC patients.
WoS Q Kategorisi
Q1Source
Annals of OncologyVolume
33Issue
Supplement:4Collections
- Bildiri Koleksiyonu [516]
- WoS İndeksli Yayınlar Koleksiyonu [6677]